Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ

Progress in Lipid Research

Volumn 64, Issue , 2016, Pages 98-122

  Tan, Nguan Soon ^a,b,c,d   Vázquez Carrera, Manuel ^e   Montagner, Alexandra ^f   Sng, Ming Keat ^a,b   Guillou, Hervé ^f   Wahli, Walter ^b,f,g  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^d KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^e UNIVERSITY OF BARCELONA   (Spain)

^f TOXALIM RESEARCH CENTRE IN FOOD TOXICOLOGY   (France)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; ATORVASTATIN; CER 002; ELAFIBRANOR; GW 610742; MBX 8025; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; SAROGLITAZAR; UNCLASSIFIED DRUG; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARCINOGENESIS; CELLULAR DISTRIBUTION; COLORECTAL CARCINOMA; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FETUS DEVELOPMENT; GAMETE; GENE REPRESSION; HEART DISEASE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIVER REGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PREIMPLANTATION EMBRYO; PRIORITY JOURNAL; REPRODUCTION; REVIEW; SKIN CARCINOMA; SPINAL CORD INJURY; TISSUE REPAIR; TRANSACTIVATION; TRANSCRIPTION REGULATION; WOUND; WOUND CLOSURE; WOUND HEALING; ANIMAL; CARDIOVASCULAR DISEASE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MUSCLE; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REGENERATION; SKIN;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; MUSCLES; NEOPLASMS; NERVOUS SYSTEM DISEASES; PPAR DELTA; PPAR-BETA; REACTIVE OXYGEN SPECIES; REGENERATION; SKIN; TRANSCRIPTION, GENETIC;

EID: 84989344365     PISSN: 01637827     EISSN: 18732194     Source Type: Journal    
DOI: 10.1016/j.plipres.2016.09.001     Document Type: Review

References (321)

1. [1] Issemann, I., Green, S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990), 645–650.
2. [2] Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., Wahli, W., Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68 (1992), 879–887.
3. [3] Kliewer, S.A., Forman, B.M., Blumberg, B., Ong, E.S., Borgmeyer, U., Mangelsdorf, D.J., Umesono, K., Evans, R.M., Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 7355–7359.
4. [4] Wahli, W., Michalik, L., PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol. Metab. 23 (2012), 351–363.
5. [5] Desvergne, B., Wahli, W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20 (1999), 649–688.
6. [6] Lalloyer, F., Staels, B., Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler. Thromb. Vasc. Biol. 30 (2010), 894–899.
7. [7] Soccio, R.E., Chen, E.R., Lazar, M.A., Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 20 (2014), 573–591.
8. [8] Sprecher, D.L., Massien, C., Pearce, G., Billin, A.N., Perlstein, I., Willson, T.M., Hassall, D.G., Ancellin, N., Patterson, S.D., Lobe, D.C., Johnson, T.G., Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor agonist. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 359–365.
9. [9] Riserus, U., Sprecher, D., Johnson, T., Olson, E., Hirschberg, S., Liu, A., Fang, Z., Hegde, P., Richards, D., Sarov-Blat, L., Strum, J.C., Basu, S., Cheeseman, J., Fielding, B.A., Humphreys, S.M., Danoff, T., Moore, N.R., Murgatroyd, P., O'Rahilly, S., Sutton, P., Willson, T., Hassall, D., Frayn, K.N., Karpe, F., Activation of peroxisome proliferator-activated receptor (PPAR) promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57 (2008), 332–339.
10. [10] Higashiyama, H., Billin, A.N., Okamoto, Y., Kinoshita, M., Asano, S., Expression profiling of peroxisome proliferator-activated receptor-delta (PPAR-delta) in mouse tissues using tissue microarray. Histochem. Cell Biol. 127 (2007), 485–494.
11. [11] Braissant, O., Foufelle, F., Scotto, C., Dauça, M., Wahli, W., Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137 (1996), 354–366.
12. [12] Yessoufou, A., Wahli, W., Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med. Wkly., 140, 2010, w13071.
13. [13] Sever, R., Glass, C.K., Signaling by nuclear receptors. Cold Spring Harb. Perspect. Biol., 5, 2013, a016709.
14. [14] Wolfrum, C., Borrmann, C.M., Borchers, T., Spener, F., Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 2323–2328.
15. [15] Tan, N.S., Shaw, N.S., Vinckenbosch, N., Liu, P., Yasmin, R., Desvergne, B., Wahli, W., Noy, N., Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol. Cell. Biol. 22 (2002), 5114–5127.
16. [16] Smathers, R.L., Petersen, D.R., The human fatty acid-binding protein family: evolutionary divergences and functions. Hum. Genomics 5 (2011), 170–191.
17. [17] Schug, T.T., Berry, D.C., Shaw, N.S., Travis, S.N., Noy, N., Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129 (2007), 723–733.
18. [18] Bando, Y., Yamamoto, M., Sakiyama, K., Inoue, K., Takizawa, S., Owada, Y., Iseki, S., Kondo, H., Amano, O., Expression of epidermal fatty acid binding protein (E-FABP) in septoclasts in the growth plate cartilage of mice. J. Mol. Histol. 45 (2014), 507–518.
19. [19] Yu, S., Levi, L., Casadesus, G., Kunos, G., Noy, N., Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor β/δ (PPARβ/δ) in the brain. J. Biol. Chem. 289 (2014), 12748–12758.
20. [20] Morgan, E., Kannan-Thulasiraman, P., Noy, N., Involvement of fatty acid binding protein 5 and PPARβ/δ in prostate cancer cell growth. PPAR Res. 2010 (2010), 1–9.
21. [21] Chen, N.-N., Li, Y., Wu, M.-L., Liu, Z.-L., Fu, Y.-S., Kong, Q.-Y., Chen, X.-Y., Li, H., Liu, J., CRABP-II- and FABP5-independent all-trans retinoic acid resistance in COLO 16 human cutaneous squamous cancer cells. Exp. Dermatol. 21 (2012), 13–18.
22. [22] Maeda, K., Uysal, K.T., Makowski, L., Gorgun, C.Z., Atsumi, G., Parker, R.A., Bruning, J., Hertzel, A.V., Bernlohr, D.A., Hotamisligil, G.S., Role of the fatty acid binding protein mal1 in obesity and insulin resistance. Diabetes 52 (2003), 300–307.
23. [23] Berry, D.C., Noy, N., All-trans-retinoic acid represses obesity and insulin resistance by activating both peroxisome proliferation-activated receptor beta/delta and retinoic acid receptor. Mol. Cell. Biol. 29 (2009), 3286–3296.
24. [24] Shi, Y., Hon, M., Evans, R.M., The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 2613–2618.
25. [25] Krogsdam, A.-M., Nielsen, C.A.F., Neve, S., Holst, D., Helledie, T., Thomsen, B., Bendixen, C., Mandrup, S., Kristiansen, K., Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor δ-mediated transactivation. Biochem. J. 363 (2002), 157–165.
26. [26] Aarenstrup, L., Flindt, E.N., Otkjaer, K., Kirkegaard, M., Andersen, J.S., Kristiansen, K., HDAC activity is required for p65/RelA-dependent repression of PPARδ-mediated transactivation in human keratinocytes. J. Investig. Dermatol. 128 (2008), 1095–1106.
27. [27] Germain, P., Bourguet, W., Dimerization of nuclear receptors. Methods Cell Biol. 117 (2013), 21–41.
28. [28] Fan, Y., Wang, Y., Tang, Z., Zhang, H., Qin, X., Zhu, Y., Guan, Y., Wang, X., Staels, B., Chien, S., Wang, N., Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28 (2008), 315–321.
29. [29] Takata, Y., Liu, J., Yin, F., Collins, A.R., Lyon, C.J., Lee, C.H., Atkins, A.R., Downes, M., Barish, G.D., Evans, R.M., Hsueh, W.A., Tangirala, R.K., PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 4277–4282.
30. [30] Piqueras, L., Reynolds, A.R., Hodivala-Dilke, K.M., Alfranca, A., Redondo, J.M., Hatae, T., Tanabe, T., Warner, T.D., Bishop-Bailey, D., Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 63–69.
31. [31] Perissi, V., Jepsen, K., Glass, C.K., Rosenfeld, M.G., Deconstructing repression: evolving models of co-repressor action. Nat. Rev. Genet. 11 (2010), 109–123.
32. [32] Mouchiroud, L., Eichner, L.J., Shaw, R.J., Auwerx, J., Transcriptional coregulators: fine-tuning metabolism. Cell Metab. 20 (2014), 26–40.
33. [33] Zhang, J., Fu, M., Zhu, X., Xiao, Y., Mou, Y., Zheng, H., Akinbami, M.A., Wang, Q., Chen, Y.E., Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. J. Biol. Chem. 277 (2002), 11505–11512.
34. [34] Ravaux, L., Denoyelle, C., Monne, C., Limon, I., Raymondjean, M., El Hadri, K., Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the proto-oncogene BCL-6. Mol. Cell. Biol. 27 (2007), 8374–8387.
35. [35] Lee, C.H., Chawla, A., Urbiztondo, N., Liao, D., Boisvert, W.A., Evans, R.M., Curtiss, L.K., Transcriptional repression of atherogenic inflammation: modulation by PPAR delta. Science 302 (2003), 453–457.
36. [36] Matsushita, Y., Ogawa, D., Wada, J., Yamamoto, N., Shikata, K., Sato, C., Tachibana, H., Toyota, N., Makino, H., Activation of peroxisome proliferator–activated receptor δ inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice. Diabetes 60 (2011), 960–968.
37. [37] Tan, N.S., Icre, G., Montagner, A., Heggeler, B.B.T., Wahli, W., Michalik, L., The nuclear hormone receptor peroxisome proliferator-activated receptor beta/delta potentiates cell chemotactism, polarization, and migration. Mol. Cell. Biol. 27 (2007), 7161–7175.
38. [38] Rotman, N., Michalik, L., Desvergne, B., Wahli, W., PPARs in fetal and early postnatal development. Taneja, R., (eds.) Nuclear Receptors in Development, 2006, Elsevier, Amsterdam, 430.
39. [39] Krey, G., Keller, H., Mahfoudi, A., Medin, J., Ozato, K., Dreyer, C., Wahli, W., Xenopus peroxisome proliferator activated receptors: genomic organization, response element recognition, heterodimer formation with retinoid X receptor and activation by fatty acids. J. Steroid Biochem. Mol. Biol. 47 (1993), 65–73.
40. [40] Wahli, W., Devchand, P.R., Jpenberg, A.I., Desvergne, B., Fatty acids, eicosanoids, and hypolipidemic agents regulate gene expression through direct binding to peroxisome proliferator-activated receptors. Adv. Exp. Med. Biol. 447 (1999), 199–209.
41. [41] Bell, E., Ponthan, F., Whitworth, C., Westermann, F., Thomas, H., Redfern, C.P.F., Cell survival signalling through PPARδ and arachidonic acid metabolites in neuroblastoma. PLoS One, 8, 2013, e68859.
42. [42] Zhang, J., Liu, X., Xie, X.-B., Cheng, X.-C., Wang, R.-L., Multitargeted bioactive ligands for PPARs discovered in the last decade. Chem. Biol. Drug Des., 2016.
43. [43] Krey, G., Braissant, O., L'Horset, F., Kalkhoven, E., Perroud, M., Parker, M.G., Wahli, W., Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11 (1997), 779–791.
44. [44] Grygiel-Górniak, B., Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review. Nutr. J., 13, 2014, 17.
45. [45] Riahi, Y., Sin-Malia, Y., Cohen, G., Alpert, E., Gruzman, A., Eckel, J., Staels, B., Guichardant, M., Sasson, S., The natural protective mechanism against hyperglycemia in vascular endothelial cells: roles of the lipid peroxidation product 4-hydroxydodecadienal and peroxisome proliferator-activated receptor delta. Diabetes 59 (2010), 808–818.
46. [46] Cohen, G., Riahi, Y., Sunda, V., Deplano, S., Chatgilialoglu, C., Ferreri, C., Kaiser, N., Sasson, S., Signaling properties of 4-hydroxyalkenals formed by lipid peroxidation in diabetes. Free Radic. Biol. Med. 65 (2013), 978–987.
47. [47] Coleman, J.D., Prabhu, K.S., Thompson, J.T., Reddy, P.S., Peters, J.M., Peterson, B.R., Reddy, C.C., Vanden Heuvel, J.P., The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-β/δ (PPARβ/δ). Free Radic. Biol. Med. 42 (2007), 1155–1164.
48. [48] Shaw, N., Elholm, M., Noy, N., Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor beta/delta. J. Biol. Chem. 278 (2003), 41589–41592.
49. [49] Levi, L., Wang, Z., Doud, M.K., Hazen, S.L., Noy, N., Saturated fatty acids regulate retinoic acid signalling and suppress tumorigenesis by targeting fatty acid-binding protein 5. Nat. Commun., 6, 2015, 8794.
50. [50] Dong, D., Ruuska, S.E., Levinthal, D.J., Noy, N., Distinct roles for cellular retinoic acid-binding proteins I and II in regulating signaling by retinoic acid. J. Biol. Chem. 274 (1999), 23695–23698.
51. [51] Budhu, A.S., Noy, N., Direct channeling of retinoic acid between cellular retinoic acid-binding protein II and retinoic acid receptor sensitizes mammary carcinoma cells to retinoic acid-induced growth arrest. Mol. Cell. Biol. 22 (2002), 2632–2641.
52. [52] Sessler, R.J., Noy, N., A ligand-activated nuclear localization signal in cellular retinoic acid binding protein-II. Mol. Cell 18 (2005), 343–353.
53. [53] Armstrong, E.H., Goswami, D., Griffin, P.R., Noy, N., Ortlund, E.A., Structural basis for ligand regulation of the fatty acid-binding protein 5, peroxisome proliferator-activated receptor β/δ (FABP5-PPARβ/δ) signaling pathway. J. Biol. Chem. 289 (2014), 14941–14954.
54. [54] Donato, L.J., Suppression of mammary carcinoma growth by retinoic acid: proapoptotic genes are targets for retinoic acid receptor and cellular retinoic acid-binding protein II signaling. Cancer Res. 65 (2005), 8193–8199.
55. [55] Donato, L.J., Suh, J.H., Noy, N., Suppression of mammary carcinoma cell growth by retinoic acid: the cell cycle control gene Btg2 is a direct target for retinoic acid receptor signaling. Cancer Res. 67 (2007), 609–615.
56. [56] Adamson, J., Morgan, E.A., Beesley, C., Mei, Y., Foster, C.S., Fujii, H., Rudland, P.S., Smith, P.H., Ke, Y., High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity. Oncogene 22 (2003), 2739–2749.
57. [57] Kawaguchi, K., Senga, S., Kubota, C., Kawamura, Y., Ke, Y., Fujii, H., High expression of fatty acid-binding protein 5 promotes cell growth and metastatic potential of colorectal cancer cells. FEBS Open Bi 6 (2016), 190–199.
58. [58] Rhodes, D.R., Kalyana-Sundaram, S., Mahavisno, V., Varambally, R., Yu, J., Briggs, B.B., Barrette, T.R., Anstet, M.J., Kincead-Beal, C., Kulkarni, P., Varambally, S., Ghosh, D., Chinnaiyan, A.M., Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9 (2007), 166–180.
59. [59] Compendia goes clinical. Cancer Disc., 2, 2012, 10.1158/2159-NB2012-128 OF2.
60. [60] Schug, T.T., Berry, D.C., Toshkov, I.A., Cheng, L., Nikitin, A.Y., Noy, N., Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 7546–7551.
61. [61] Kannan-Thulasiraman, P., Seachrist, D.D., Mahabeleshwar, G.H., Jain, M.K., Noy, N., Fatty acid-binding protein 5 and PPARbeta/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. J. Biol. Chem. 285 (2010), 19106–19115.
62. [62] Levi, L., Lobo, G., Doud, M.K., von Lintig, J., Seachrist, D., Tochtrop, G.P., Noy, N., Genetic ablation of the fatty acid-binding protein FABP5 suppresses HER2-induced mammary tumorigenesis. Cancer Res. 73 (2013), 4770–4780.
63. [63] Rieck, M., Meissner, W., Ries, S., Muller-Brusselbach, S., Muller, R., Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid. Mol. Pharmacol. 74 (2008), 1269–1277.
64. [64] Bortolotto, J.W., Margis, R., Ferreira, Â.C.B., Padoin, A.V., Mottin, C.C., Guaragna, R.M., Adipose tissue distribution and quantification of PPARbeta/delta and PPARgamma1-3 mRNAs: discordant gene expression in subcutaneous, retroperitoneal and visceral adipose tissue of morbidly obese patients. Obes. Surg. 17 (2007), 934–940.
65. [65] Yu, S., Levi, L., Siegel, R., Noy, N., Retinoic acid induces neurogenesis by activating both retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor β/δ (PPARβ/δ). J. Biol. Chem. 287 (2012), 42195–42205.
66. [66] Mackenzie, L.S., Lione, L., Harnessing the benefits of PPARβ/δ agonists. Life Sci. 93 (2013), 963–967.
67. [67] Gillilan, R.E., Ayers, S.D., Noy, N., Structural basis for activation of fatty acid-binding protein 4. J. Mol. Biol. 372 (2007), 1246–1260.
68. [68] Ayers, S.D., Nedrow, K.L., Gillilan, R.E., Noy, N., Continuous nucleocytoplasmic shuttling underlies transcriptional activation of PPARgamma by FABP4. Biochemistry 46 (2007), 6744–6752.
69. [69] Schupp, M., Curtin, J.C., Kim, R.J., Billin, A.N., Lazar, M.A., A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-gamma activity. Mol. Pharmacol. 71 (2007), 1251–1257.
70. [70] Rotman, N., Guex, N., Gouranton, E., Wahli, W., PPARβ interprets a chromatin signature of pluripotency to promote embryonic differentiation at gastrulation. PLoS One, 8, 2013, e83300.
71. [71] Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R., Koder, A., Evans, R.M., PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 4 (1999), 585–595.
72. [72] Barak, Y., Liao, D., He, W., Ong, E.S., Nelson, M.C., Olefsky, J.M., Boland, R., Evans, R.M., Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 303–308.
73. [73] Nadra, K., Anghel, S.I., Joye, E., Tan, N.S., Basu-Modak, S., Trono, D., Wahli, W., Desvergne, B., Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol. Cell. Biol. 26 (2006), 3266–3281.
74. [74] Huin, C., Corriveau, L., Bianchi, A., Keller, J.M., Collet, P., Kremarik-Bouillaud, P., Domenjoud, L., Becuwe, P., Schohn, H., Menard, D., Dauca, M., Differential expression of peroxisome proliferator-activated receptors (PPARs) in the developing human fetal digestive tract. J. Histochem. Cytochem. 48 (2000), 603–611.
75. [75] Abbott, B.D., Wood, C.R., Watkins, A.M., Das, K.P., Lau, C.S., Peroxisome proliferator-activated receptors alpha, beta, and gamma mRNA and protein expression in human fetal tissues. PPAR Res. 2010 (2010), 1–2.
76. [76] Braissant, O., Wahli, W., Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 139 (1998), 2748–2754.
77. [77] Han, K., Song, H., Moon, I., Augustin, R., Moley, K., Rogers, M., Lim, H., Utilization of DR1 as true RARE in regulating the Ssm, a novel retinoic acid-target gene in the mouse testis. J. Endocrinol. 192 (2007), 539–551.
78. [78] Pakrasi, P.L., Jain, A.K., Evaluation of cyclooxygenase 2 derived endogenous prostacyclin in mouse preimplantation embryo development in vitro. Life Sci. 80 (2007), 1503–1507.
79. [79] Huang, J.C., Wun, W.S.A., Goldsby, J.S., Wun, I.C., Noorhasan, D., Wu, K.K., Stimulation of embryo hatching and implantation by prostacyclin and peroxisome proliferator-activated receptor delta activation: implication in IVF. Hum. Reprod. 22 (2007), 807–814.
80. [80] Huang, J.-C., The role of peroxisome proliferator-activated receptors in the development and physiology of gametes and preimplantation embryos. PPAR Res., 2008, 2008, 732303.
81. [81] Peters, J.M., Lee, S.S.T., Li, W., Ward, J.M., Gavrilova, O., Everett, C., Reitman, M.L., Hudson, L.D., Gonzalez, F.J., Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol. Cell. Biol. 20 (2000), 5119–5128.
82. [82] Michalik, L., Desvergne, B., Tan, N.S., Basu-Modak, S., Escher, P., Rieusset, J., Peters, J.M., Kaya, G., Gonzalez, F.J., Zakany, J., Metzger, D., Chambon, P., Duboule, D., Wahli, W., Impaired skin wound healing in peroxisome proliferator–activated receptor (PPAR) α and PPAR β mutant mice. J. Cell Biol. 154 (2001), 799–814.
83. [83] Wang, H., Xie, H., Sun, X., Tranguch, S., Zhang, H., Jia, X., Wang, D., Das, S.K., Desvergne, B., Wahli, W., DuBois, R.N., Dey, S.K., Stage-specific integration of maternal and embryonic peroxisome proliferator-activated receptor delta signaling is critical to pregnancy success. J. Biol. Chem. 282 (2007), 37770–37782.
84. [84] Huang, J.C., Wun, W.S.A., Goldsby, J.S., Matijevic-Aleksic, N., Wu, K.K., Cyclooxygenase-2-derived endogenous prostacyclin enhances mouse embryo hatching. Hum. Reprod. 19 (2004), 2900–2906.
85. [85] Huang, J.C., Goldsby, J.S., Wun, W.S.A., Prostacyclin enhances the implantation and live birth potentials of mouse embryos. Hum. Reprod. 19 (2004), 1856–1860.
86. [86] Liu, C., Lee, M., Hsieh, C., Huang, C., Tsao, H., Hsieh, Y., Prostacyclin enhances mouse embryo development and hatching but not increased embryonic cell number and volume. Fertil. Steril. 86 (2006), 1047–1052.
87. [87] Kang, H.J., Hwang, S.J., Yoon, J.A., Jun, J.H., Lim, H.J., Yoon, T.K., Song, H., Activation of peroxisome proliferators-activated receptor δ (PPARδ) promotes blastocyst hatching in mice. Mol. Hum. Reprod. 17 (2011), 653–660.
88. [88] Nishimura, K., Nakano, N., Chowdhury, V.S., Kaneto, M., Torii, M., Hattori, M.-A., Yamauchi, N., Kawai, M., Effect of PPARβ/δ agonist on the placentation and embryo-fetal development in rats. Birth Defects Res. B Dev. Reprod. Toxicol. 98 (2013), 164–169.
89. [89] Zuo, X., Peng, Z., Moussalli, M.J., Morris, J.S., Broaddus, R.R., Fischer, S.M., Shureiqi, I., Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. J. Natl. Cancer Inst. 101 (2009), 762–767.
90. [90] Wang, D., Fu, L., Ning, W., Guo, L., Sun, X., Dey, S.K., Chaturvedi, R., Wilson, K.T., DuBois, R.N., Peroxisome proliferator-activated receptor δ promotes colonic inflammation and tumor growth. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 7084–7089.
91. [91] Michalik, L., Wahli, W., Involvement of PPAR nuclear receptors in tissue injury and wound repair. J. Clin. Investig. 116 (2006), 598–606.
92. [92] Martin, P., Nunan, R., Cellular and molecular mechanisms of repair in acute and chronic wound healing. Br. J. Dermatol. 173 (2015), 370–378.
93. [93] Bensinger, S.J., Tontonoz, P., Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454 (2008), 470–477.
94. [94] Devchand, P.R., Keller, H., Peters, J.M., Vazquez, M., Gonzalez, F.J., Wahli, W., The PPARα–leukotriene B4 pathway to inflammation control. Nature 384 (1996), 39–43.
95. [95] Alleva, D.G., Johnson, E.B., Lio, F.M., Boehme, S.A., Conlon, P.J., Crowe, P.D., Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma. J. Leukoc. Biol. 71 (2002), 677–685.
96. [96] Welch, J.S., Ricote, M., Akiyama, T.E., Gonzalez, F.J., Glass, C.K., PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 6712–6717.
97. [97] Kilgore, K.S., Billin, A.N., PPARbeta/delta ligands as modulators of the inflammatory response. Curr. Opin. Investig. Drugs 9 (2008), 463–469.
98. [98] Tan, N.S., Michalik, L., Desvergne, B., Wahli, W., Peroxisome proliferator-activated receptor-β as a target for wound healing drugs. Expert Opin. Ther. Targets 8 (2004), 39–48.
99. [99] Tan, N.S., Michalik, L., Di-Poï, N., Desvergne, B., Wahli, W., Critical roles of the nuclear receptor PPARβ (peroxisome-proliferator-activated receptor β) in skin wound healing. Biochem. Soc. Trans. 32 (2004), 97–102.
100. [100] Di-Poï, N., Tan, N.S., Michalik, L., Wahli, W., Desvergne, B., Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol. Cell 10 (2002), 721–733.
101. [101] Caley, M.P., Martins, V.L.C., O'Toole, E.A., Metalloproteinases and wound healing. Adv. Wound Care 4 (2015), 225–234.
102. [102] Chong, H.C., Tan, M.J., Philippe, V., Tan, S.H., Tan, C.K., Ku, C.W., Goh, Y.Y., Wahli, W., Michalik, L., Tan, N.S., Regulation of epithelial–mesenchymal IL-1 signaling by PPARβ/δ is essential for skin homeostasis and wound healing. J. Cell Biol. 184 (2009), 817–831.
103. [103] Wang, X., Sng, M.K., Foo, S., Chong, H.C., Lee, W.L., Tang, M.B.Y., Ng, K.W., Luo, B., Choong, C., Wong, M.T.C., Tong, B.M.K., Chiba, S., Loo, S.C.J., Zhu, P., Tan, N.S., Early controlled release of peroxisome proliferator-activated receptor β/δ agonist GW501516 improves diabetic wound healing through redox modulation of wound microenvironment. J. Control. Release 197 (2015), 138–147.
104. [104] Ham, S.A., Yoo, T., Hwang, J.S., Kang, E.S., Paek, K.S., Park, C., Kim, J.-H., Do, J.T., Seo, H.G., Peroxisome proliferator-activated receptor δ modulates MMP-2 secretion and elastin expression in human dermal fibroblasts exposed to ultraviolet B radiation. J. Dermatol. Sci. 76 (2014), 44–50.
105. [105] Zuo, C., Liang, P., Huang, X., Role of PPARbeta in fibroblast response to heat injury. Indian J. Biochem. Biophys. 49 (2012), 219–227.
106. [106] Wietecha, M.S., DiPietro, L.A., Therapeutic approaches to the regulation of wound angiogenesis. Adv. Wound Care 2 (2013), 81–86.
107. [107] Li, J., Li, P., Zhang, Y., Li, G.-B., He, F.-T., Zhou, Y.-G., Yang, K., Dai, S.-S., Upregulation of ski in fibroblast is implicated in the peroxisome proliferator-activated receptor σ-mediated wound healing. Cell. Physiol. Biochem. 30 (2012), 1059–1071.
108. [108] Deheuninck, J., Luo, K., Ski and SnoN, potent negative regulators of TGF-β signaling. Cell Res. 19 (2009), 47–57.
109. [109] Ham, S.A., Hwang, J.S., Yoo, T., Lee, W.J., Paek, K.S., Oh, J.-W., Park, C.-K., Kim, J.-H., Do, J.T., Kim, J.-H., Seo, H.G., Ligand-activated PPARδ upregulates α-smooth muscle actin expression in human dermal fibroblasts: a potential role for PPARδ in wound healing. J. Dermatol. Sci. 80 (2015), 186–195.
110. [110] Martin, A., Komada, M.R., Sane, D.C., Abnormal angiogenesis in diabetes mellitus. Med. Res. Rev. 23 (2003), 117–145.
111. [111] Greaves, N.S., Ashcroft, K.J., Baguneid, M., Bayat, A., Current understanding of molecular and cellular mechanisms in fibroplasia and angiogenesis during acute wound healing. J. Dermatol. Sci. 72 (2013), 206–217.
112. [112] Kersten, S., Mandard, S., Tan, N.S., Escher, P., Metzger, D., Chambon, P., Gonzalez, F.J., Desvergne, B., Wahli, W., Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 275 (2000), 28488–28493.
113. [113] Ekmektzoglou, K.A., Zografos, G.C., A concomitant review of the effects of diabetes mellitus and hypothyroidism in wound healing. World J. Gastroenterol. 12 (2006), 2721–2729.
114. [114] Zhu, P., Goh, Y.Y., Chin, H.F.A., Kersten, S., Tan, N.S., Angiopoietin-like 4: a decade of research. Biosci. Rep. 32 (2012), 211–219.
115. [115] Huang, R.L., Teo, Z., Chong, H.C., Zhu, P., Tan, M.J., Tan, C.K., Lam, C.R.I., Sng, M.K., Leong, D.T.W., Tan, S.M., Kersten, S., Ding, J.L., Li, H.Y., Tan, N.S., ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters. Blood 118 (2011), 3990–4002.
116. [116] Chong, H.C., Chan, J.S.K., Goh, C.Q., Gounko, N.V., Luo, B., Wang, X., Foo, S., Wong, M.T.C., Choong, C., Kersten, S., Tan, N.S., Angiopoietin-like 4 stimulates STAT3-mediated iNOS expression and enhances angiogenesis to accelerate wound healing in diabetic mice. Mol. Ther. 22 (2014), 1593–1604.
117. [117] Goh, Y.Y., Pal, M., Chong, H.C., Zhu, P., Tan, M.J., Punugu, L., Tan, C.K., Huang, R.L., Sze, S.K., Tang, M.B.Y., Ding, J.L., Kersten, S., Tan, N.S., Angiopoietin-like 4 interacts with matrix proteins to modulate wound healing. J. Biol. Chem. 285 (2010), 32999–33009.
118. [118] Pal, M., Tan, M.J., Huang, R.-L., Goh, Y.Y., Wang, X.L., Tang, M.B.Y., Tan, N.S., Angiopoietin-like 4 regulates epidermal differentiation. PLoS One, 6, 2011, e25377.
119. [119] Bornstein, P., Sage, E.H., Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 14 (2002), 608–616.
120. [120] Goh, Y.Y., Pal, M., Chong, H.C., Zhu, P., Tan, M.J., Punugu, L., Lam, C.R.I., Yau, Y.H., Tan, C.K., Huang, R.-L., Tan, S.M., Tang, M.B.Y., Ding, J.L., Kersten, S., Tan, N.S., Angiopoietin-like 4 interacts with integrins β1 and β5 to modulate keratinocyte migration. Am. J. Pathol. 177 (2010), 2791–2803.
121. [121] Chan, J.S., Teo, Z., Sng, M.K., Tan, N.S., Probing for protein-protein interactions during cell migration: limitations and challenges. Histol. Histopathol. 29 (2014), 965–976.
122. [122] Gu, Y., Li, X., He, T., Jiang, Z., Hao, P., Tang, X., The antifibrosis effects of peroxisome proliferator-activated receptorδ on rat corneal wound healing after excimer laser keratectomy. PPAR Res., 2014, 2014, 464935.
123. [123] Ali, F., Ali, N.S., Bauer, A., Boyle, J.J., Hamdulay, S.S., Haskard, D.O., Randi, A.M., Mason, J.C., PPARdelta and PGC1alpha act cooperatively to induce haem oxygenase-1 and enhance vascular endothelial cell resistance to stress. Cardiovasc. Res. 85 (2010), 701–710.
124. [124] Pang, M., de la Monte, S.M., Longato, L., Tong, M., He, J., Chaudhry, R., Duan, K., Ouh, J., Wands, J.R., PPARδ agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J. Hepatol. 50 (2009), 1192–1201.
125. [125] Ehrenborg, E., Skogsberg, J., Peroxisome proliferator-activated receptor delta and cardiovascular disease. Atherosclerosis 231 (2013), 95–106.
126. [126] Jimenez, R., Sanchez, M., Zarzuelo, M.J., Romero, M., Quintela, A.M., Lopez-Sepulveda, R., Galindo, P., Gomez-Guzman, M., Haro, J.M., Zarzuelo, A., Perez-Vizcaino, F., Duarte, J., Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor beta agonists via the phosphatidyl-inositol-3 kinase-Akt pathway. J. Pharmacol. Exp. Ther. 332 (2010), 554–561.
127. [127] Quintela, A.M., Jiménez, R., Gómez-Guzmán, M., Zarzuelo, M.J., Galindo, P., Sánchez, M., Vargas, F., Cogolludo, Á., Tamargo, J., Pérez-Vizcaíno, F., Duarte, J., Activation of peroxisome proliferator-activated receptor-β/-δ (PPARβ/δ) prevents endothelial dysfunction in type 1 diabetic rats. Free Radic. Biol. Med. 53 (2012), 730–741.
128. [128] Tian, X.Y., Wong, W.T., Wang, N., Lu, Y., Cheang, W.S., Liu, J., Liu, L., Liu, Y., Lee, S.S.T., Chen, Z.Y., Cooke, J.P., Yao, X., Huang, Y., PPARδ activation protects endothelial function in diabetic mice. Diabetes 61 (2012), 3285–3293.
129. [129] Toral, M., Romero, M., Jiménez, R., Mahmoud, A.M., Barroso, E., Gómez-Guzmán, M., Sánchez, M., Cogolludo, Á., García-Redondo, A.B., Briones, A.M., Vázquez-Carrera, M., Pérez-Vizcaíno, F., Duarte, J., Carnitine palmitoyltransferase-1 up-regulation by PPAR-β/δ prevents lipid-induced endothelial dysfunction. Clin. Sci. 129 (2015), 823–837.
130. [130] Zarzuelo, M.J., Jimenez, R., Galindo, P., Sanchez, M., Nieto, A., Romero, M., Quintela, A.M., Lopez-Sepulveda, R., Gomez-Guzman, M., Bailon, E., Rodriguez-Gomez, I., Zarzuelo, A., Galvez, J., Tamargo, J., Perez-Vizcaino, F., Duarte, J., Antihypertensive effects of peroxisome proliferator-activated receptor-β activation in spontaneously hypertensive rats. Hypertension 58 (2011), 733–743.
131. [131] Bansal, G., Druey, K.M., Xie, Z., R4 RGS proteins: regulation of G-protein signaling and beyond. Pharmacol. Ther. 116 (2007), 473–495.
132. [132] Heximer, S.P., Knutsen, R.H., Sun, X., Kaltenbronn, K.M., Rhee, M.-H., Peng, N., Oliveira-dos-Santos, A., Penninger, J.M., Muslin, A.J., Steinberg, T.H., Wyss, J.M., Mecham, R.P., Blumer, K.J., Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J. Clin. Investig. 111 (2003), 445–452.
133. [133] Cheang, W.S., Tian, X.Y., Wong, W.T., Lau, C.W., Lee, S.S.T., Chen, Z.Y., Yao, X., Wang, N., Huang, Y., Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5′ adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor δ pathway. Arterioscler. Thromb. Vasc. Biol. 34 (2014), 830–836.
134. [134] Akiyama, T.E., Lambert, G., Nicol, C.J., Matsusue, K., Peters, J.M., Brewer, H.B., Gonzalez, F.J., Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet. J. Biol. Chem. 279 (2004), 20874–20881.
135. [135] Leibowitz, M.D., Fiévet, C., Hennuyer, N., Peinado-Onsurbe, J., Duez, H., Berger, J., Cullinan, C.A., Sparrow, C.P., Baffic, J., Berger, G.D., Santini, C., Marquis, R.W., Tolman, R.L., Smith, R.G., Moller, D.E., Auwerx, J., Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett. 473 (2000), 333–336.
136. [136] Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R.X., Tachibana, K., Watanabe, Y., Uchiyama, Y., Sumi, K., Iguchi, H., Ito, S., Doi, T., Hamakubo, T., Naito, M., Auwerx, J., Yanagisawa, M., Kodama, T., Sakai, J., Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 15924–15929.
137. [137] Barroso, E., Rodríguez-Calvo, R., Serrano-Marco, L., Astudillo, A.M., Balsinde, J., Palomer, X., Vázquez-Carrera, M., The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-lipin 1-PPARα pathway leading to increased fatty acid oxidation. Endocrinology 152 (2011), 1848–1859.
138. [138] Sanderson, L.M., Boekschoten, M.V., Desvergne, B., Muller, M., Kersten, S., Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation of gene expression in mouse liver. Physiol. Genomics 41 (2010), 42–52.
139. [139] Oliver, W.R., Shenk, J.L., Snaith, M.R., Russell, C.S., Plunket, K.D., Bodkin, N.L., Lewis, M.C., Winegar, D.A., Sznaidman, M.L., Lambert, M.H., Xu, H.E., Sternbach, D.D., Kliewer, S.A., Hansen, B.C., Willson, T.M., A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 5306–5311.
140. [140] Chehaibi, K., Cedó, L., Metso, J., Palomer, X., Santos, D., Quesada, H., Naceur Slimane, M., Wahli, W., Julve, J., Vázquez-Carrera, M., Jauhiainen, M., Blanco-Vaca, F., Escolà-Gil, J.C., PPAR-β/δ activation promotes phospholipid transfer protein expression. Biochem. Pharmacol. 94 (2015), 101–108.
141. [141] van der Veen, J.N., Kruit, J.K., Havinga, R., Baller, J.F., Chimini, G., Lestavel, S., Staels, B., Groot, P.H., Groen, A.K., Kuipers, F., Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J. Lipid Res. 46 (2005), 526–534.
142. [142] Vrins, C.L.J., van der Velde, A.E., van den Oever, K., Levels, J.H.M., Huet, S., Oude Elferink, R.P.J., Kuipers, F., Groen, A.K., Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux. J. Lipid Res. 50 (2009), 2046–2054.
143. [143] Ooi, E.M.M., Watts, G.F., Sprecher, D.L., Chan, D.C., Barrett, P.H.R., Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-δ agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J. Clin. Endocrinol. Metab. 96 (2011), E1568–E1576.
144. [144] Olson, E.J., Pearce, G.L., Jones, N.P., Sprecher, D.L., Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 2289–2294.
145. [145] Choi, Y.-J., Roberts, B.K., Wang, X., Geaney, J.C., Naim, S., Wojnoonski, K., Karpf, D.B., Krauss, R.M., Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis 220 (2012), 470–476.
146. [146] Bays, H.E., Schwartz, S., Littlejohn, T., Kerzner, B., Krauss, R.M., Karpf, D.B., Choi, Y.-J., Wang, X., Naim, S., Roberts, B.K., MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J. Clin. Endocrinol. Metab. 96 (2011), 2889–2897.
147. [147] Graham, T.L., Mookherjee, C., Suckling, K.E., Palmer, C.N., Patel, L., The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(−/−) mice. Atherosclerosis 181 (2005), 29–37.
148. [148] Barish, G.D., Atkins, A.R., Downes, M., Olson, P., Chong, L.W., Nelson, M., Zou, Y., Hwang, H., Kang, H., Curtiss, L., Evans, R.M., Lee, C.H., PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 4271–4276.
149. [149] Bojic, L.A., Burke, A.C., Chhoker, S.S., Telford, D.E., Sutherland, B.G., Edwards, J.Y., Sawyez, C.G., Tirona, R.G., Yin, H., Pickering, J.G., Huff, M.W., Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 34 (2014), 52–60.
150. [150] Li, A.C., Binder, C.J., Gutierrez, A., Brown, K.K., Plotkin, C.R., Pattison, J.W., Valledor, A.F., Davis, R.A., Willson, T.M., Witztum, J.L., Palinski, W., Glass, C.K., Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J. Clin. Investig. 114 (2004), 1564–1576.
151. [151] Cheng, L., Ding, G., Qin, Q., Huang, Y., Lewis, W., He, N., Evans, R.M., Schneider, M.D., Brako, F.A., Xiao, Y., Chen, Y.E., Yang, Q., Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10 (2004), 1245–1250.
152. [152] Wang, P., Liu, J., Li, Y., Wu, S., Luo, J., Yang, H., Subbiah, R., Chatham, J., Zhelyabovska, O., Yang, Q., Peroxisome proliferator-activated receptor δ is an essential transcriptional regulator for mitochondrial protection and biogenesis in adult heart. Circ. Res. 106 (2010), 911–919.
153. [153] Burkart, E.M., Sambandam, N., Han, X., Gross, R.W., Courtois, M., Gierasch, C.M., Shoghi, K., Welch, M.J., Kelly, D.P., Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart. J. Clin. Investig. 117 (2007), 3930–3939.
154. [154] Liu, J., Wang, P., Luo, J., Huang, Y., He, L., Yang, H., Li, Q., Wu, S., Zhelyabovska, O., Yang, Q., Peroxisome proliferator-activated receptor β/δ activation in adult hearts facilitates mitochondrial function and cardiac performance under pressure-overload condition. Hypertension 57 (2011), 223–230.
155. [155] Yue, T.L., Nerurkar, S.S., Bao, W., Jucker, B.M., Sarov-Blat, L., Steplewski, K., Ohlstein, E.H., Willette, R.N., In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats. J. Pharmacol. Exp. Ther. 325 (2008), 466–474.
156. [156] el Azzouzi, H., Leptidis, S., Dirkx, E., Hoeks, J., van Bree, B., Brand, K., McClellan, E.A., Poels, E., Sluimer, J.C., van den Hoogenhof, M.M.G., Armand, A.-S., Yin, X., Langley, S., Bourajjaj, M., Olieslagers, S., Krishnan, J., Vooijs, M., Kurihara, H., Stubbs, A., Pinto, Y.M., Krek, W., Mayr, M., da C. Martins, P.A., Schrauwen, P., De Windt, L.J., The hypoxia-inducible microRNA cluster miR-199a ∼ 214 targets myocardial PPARδ and impairs mitochondrial fatty acid oxidation. Cell Metab. 18 (2013), 341–354.
157. [157] Yu, B.C., Chang, C.K., Ou, H.Y., Cheng, K.C., Cheng, J.T., Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats. Cardiovasc. Res. 80 (2008), 78–87.
158. [158] Álvarez-Guardia, D., Palomer, X., Coll, T., Serrano, L., Rodríguez-Calvo, R., Davidson, M.M., Merlos, M., El Kochairi, I., Michalik, L., Wahli, W., Vázquez-Carrera, M., PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochim. Biophys. Acta 1811 (2011), 59–67.
159. [159] Palomer, X., Capdevila-Busquets, E., Botteri, G., Salvadó, L., Barroso, E., Davidson, M.M., Michalik, L., Wahli, W., Vázquez-Carrera, M., PPARβ/δ attenuates palmitate-induced endoplasmic reticulum stress and induces autophagic markers in human cardiac cells. Int. J. Cardiol. 174 (2014), 110–118.
160. [160] Park, J.R., Ahn, J.H., Jung, M.H., Koh, J.-S., Park, Y., Hwang, S.-J., Jeong, Y.-H., Kwak, C.H., Lee, Y.S., Seo, H.G., Kim, J.H., Hwang, J.-Y., Effects of peroxisome proliferator-activated receptor-δ agonist on cardiac healing after myocardial infarction. PLoS One, 11, 2016, e0148510.
161. [161] Glass, C.K., Olefsky, J.M., Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15 (2012), 635–645.
162. [162] Kang, K., Reilly, S.M., Karabacak, V., Gangl, M.R., Fitzgerald, K., Hatano, B., Lee, C.-H., Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 7 (2008), 485–495.
163. [163] Barroso, E., Rodríguez-Rodríguez, R., Chacón, M.R., Maymó-Masip, E., Ferrer, L., Salvadó, L., Salmerón, E., Wabistch, M., Palomer, X., Vendrell, J., Wahli, W., Vázquez-Carrera, M., PPARβ/δ ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation. Biochim. Biophys. Acta 1852 (2015), 1049–1058.
164. [164] Wang, Y.-X., Lee, C.-H., Tiep, S., Yu, R.T., Ham, J., Kang, H., Evans, R.M., Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113 (2003), 159–170.
165. [165] Serrano-Marco, L., Rodriguez-Calvo, R., El Kochairi, I., Palomer, X., Michalik, L., Wahli, W., Vazquez-Carrera, M., Activation of peroxisome proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes. Diabetes 60 (2011), 1990–1999.
166. [166] Qu, D., Liu, J., Lau, C.W., Huang, Y., IL-6 in diabetes and cardiovascular complications. Br. J. Pharmacol. 171 (2014), 3595–3603.
167. [167] Zhao, Y., Gao, P., Sun, F., Li, Q., Chen, J., Yu, H., Li, L., Wei, X., He, H., Lu, Z., Wei, X., Wang, B., Cui, Y., Xiong, S., Shang, Q., Xu, A., Huang, Y., Liu, D., Zhu, Z., Sodium intake regulates glucose homeostasis through the PPARδ/adiponectin-mediated SGLT2 pathway. Cell Metab. 23 (2016), 699–711.
168. [168] DeFronzo, R.A., Tripathy, D., Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32 (2009), S157–S163.
169. [169] Luquet, S., Lopez-Soriano, J., Holst, D., Fredenrich, A., Melki, J., Rassoulzadegan, M., Grimaldi, P.A., Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J. 17 (2003), 2299–2301.
170. [170] Gan, Z., Rumsey, J., Hazen, B.C., Lai, L., Leone, T.C., Vega, R.B., Xie, H., Conley, K.E., Auwerx, J., Smith, S.R., Olson, E.N., Kralli, A., Kelly, D.P., Nuclear receptor/microRNA circuitry links muscle fiber type to energy metabolism. J. Clin. Investig. 123 (2013), 2564–2575.
171. [171] Schuler, M., Ali, F., Chambon, C., Duteil, D., Bornert, J.-M., Tardivel, A., Desvergne, B., Wahli, W., Chambon, P., Metzger, D., PGC1α expression is controlled in skeletal muscles by PPARβ, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab. 4 (2006), 407–414.
172. [172] Kleiner, S., Nguyen-Tran, V., Bare, O., Huang, X., Spiegelman, B., Wu, Z., PPAR{delta} agonism activates fatty acid oxidation via PGC-1{alpha} but does not increase mitochondrial gene expression and function. J. Biol. Chem. 284 (2009), 18624–18633.
173. [173] Ehrenborg, E., Krook, A., Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. Pharmacol. Rev. 61 (2009), 373–393.
174. [174] Liu, S., Brown, J.D., Stanya, K.J., Homan, E., Leidl, M., Inouye, K., Bhargava, P., Gangl, M.R., Dai, L., Hatano, B., Hotamisligil, G.S., Saghatelian, A., Plutzky, J., Lee, C.-H., A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use. Nature 502 (2013), 550–554.
175. [175] Salvadó, L., Barroso, E., Gómez-Foix, A.M., Palomer, X., Michalik, L., Wahli, W., Vázquez-Carrera, M., PPARβ/δ prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism. Diabetologia 57 (2014), 2126–2135.
176. [176] Staiger, H., Haas, C., Machann, J., Werner, R., Weisser, M., Schick, F., Machicao, F., Stefan, N., Fritsche, A., Haring, H.U., Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-delta and is of metabolic relevance in humans. Diabetes 58 (2009), 579–589.
177. [177] Georgiadi, A., Lichtenstein, L., Degenhardt, T., Boekschoten, M.V., van Bilsen, M., Desvergne, B., Muller, M., Kersten, S., Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor beta/delta and protects against fatty acid-induced oxidative stress. Circ. Res. 106 (2010), 1712–1721.
178. [178] Yoshida, K., Shimizugawa, T., Ono, M., Furukawa, H., Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J. Lipid Res. 43 (2002), 1770–1772.
179. [179] Mandard, S., Zandbergen, F., van Straten, E., Wahli, W., Kuipers, F., Muller, M., Kersten, S., The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J. Biol. Chem. 281 (2006), 934–944.
180. [180] Dijk, W., Beigneux, A.P., Larsson, M., Bensadoun, A., Young, S.G., Kersten, S., Angiopoietin-like 4 (ANGPTL4) promotes intracellular degradation of lipoprotein lipase in adipocytes. J. Lipid Res., 2016 (pii: jlr.M067363).
181. [181] Reilly, S.M., Lee, C.H., PPAR delta as a therapeutic target in metabolic disease. FEBS Lett. 582 (2008), 26–31.
182. [182] Minnaard, R., Schrauwen, P., Schaart, G., Jorgensen, J.A., Lenaers, E., Mensink, M., Hesselink, M.K.C., Adipocyte differentiation-related protein and OXPAT in rat and human skeletal muscle: involvement in lipid accumulation and type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 94 (2009), 4077–4085.
183. [183] Phillips, S.A., Choe, C.C., Ciaraldi, T.P., Greenberg, A.S., Kong, A.P.S., Baxi, S.C., Christiansen, L., Mudaliar, S.R., Henry, R.R., Adipocyte differentiation-related protein in human skeletal muscle: relationship to insulin sensitivity. Obes. Res. 13 (2005), 1321–1329.
184. [184] Gan, Z., Burkart-Hartman, E.M., Han, D.H., Finck, B., Leone, T.C., Smith, E.Y., Ayala, J.E., Holloszy, J., Kelly, D.P., The nuclear receptor PPARβ/δ programs muscle glucose metabolism in cooperation with AMPK and MEF2. Genes Dev. 25 (2011), 2619–2630.
185. [185] Benetti, E., Mastrocola, R., Rogazzo, M., Chiazza, F., Aragno, M., Fantozzi, R., Collino, M., Minetto, M.A., High sugar intake and development of skeletal muscle insulin resistance and inflammation in mice: a protective role for PPAR-δagonism. Mediat. Inflamm., 2013, 2013, 509502.
186. [186] Christodoulides, C., Dyson, P., Sprecher, D., Tsintzas, K., Karpe, F., Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J. Clin. Endocrinol. Metab. 94 (2009), 3594–3601.
187. [187] Ray, K., NAFLD—the next global epidemic. Nat. Rev. Gastroenterol. Hepatol., 10, 2013, 621.
188. [188] Michelotti, G.A., Machado, M.V., Diehl, A.M., NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 656–665.
189. [189] Joshi, S.R., Saroglitazar for the treatment of dyslipidemia in diabetic patients. Expert. Opin. Pharmacother. 16 (2015), 597–606.
190. [190] Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L.J., Baron, M., Lucas, A., Tailleux, A., Hum, D.W., Ratziu, V., Cariou, B., Hanf, R., Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58 (2013), 1941–1952.
191. [191] Ratziu, V., Harrison, S.A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., Drenth, J., Anstee, Q.M., Hum, D., Hanf, R., Roudot, A., Megnien, S., Staels, B., Sanyal, A., Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150 (2016), 1147–1159.e1145.
192. [192] Baraille, F., Planchais, J., Dentin, R., Guilmeau, S., Postic, C., Integration of ChREBP-mediated glucose sensing into whole body metabolism. Physiology 30 (2015), 428–437.
193. [193] Cha, J.Y., Repa, J.J., The liver X receptor (LXR) and hepatic lipogenesis: the carbohydrate-response element-binding protein is a target gene of LXR. J. Biol. Chem. 282 (2007), 743–751.
194. [194] Guillou, H., Martin, P.G.P., Pineau, T., Transcriptional regulation of hepatic fatty acid metabolism. Subcell. Biochem. 49 (2008), 3–47.
195. [195] Wang, Y., Viscarra, J., Kim, S.-J., Sul, H.S., Transcriptional regulation of hepatic lipogenesis. Nat. Rev. Mol. Cell Biol. 16 (2015), 678–689.
196. [196] Ferré, P., Foufelle, F., Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes. Metab. 12 (2010), 83–92.
197. [197] Peet, D.J., Janowski, B.A., Mangelsdorf, D.J., The LXRs: a new class of oxysterol receptors. Curr. Opin. Genet. Dev. 8 (1998), 571–575.
198. [198] Xu, J., Nakamura, M.T., Cho, H.P., Clarke, S.D., Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids: a mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J. Biol. Chem. 274 (1999), 23577–23583.
199. [199] Dentin, R., Benhamed, F., Pegorier, J.P., Foufelle, F., Viollet, B., Vaulont, S., Girard, J., Postic, C., Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. J. Clin. Invest. 115 (2005), 2843–2854.
200. [200] Yoshikawa, T., Shimano, H., Yahagi, N., Ide, T., Amemiya-Kudo, M., Matsuzaka, T., Nakakuki, M., Tomita, S., Okazaki, H., Tamura, Y., Iizuka, Y., Ohashi, K., Takahashi, A., Sone, H., Osuga, J.-I., Gotoda, T., Ishibashi, S., Yamada, N., Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J. Biol. Chem. 277 (2002), 1705–1711.
201. [201] Ducheix, S., Montagner, A., Polizzi, A., Lasserre, F., Marmugi, A., Bertrand-Michel, J., Podechard, N., Al Saati, T., Chétiveaux, M., Baron, S., Boué, J., Dietrich, G., Mselli-Lakhal, L., Costet, P., Lobaccaro, J.-M.A., Pineau, T., Theodorou, V., Postic, C., Martin, P.G.P., Guillou, H., Essential fatty acids deficiency promotes lipogenic gene expression and hepatic steatosis through the liver X receptor. J. Hepatol. 58 (2013), 984–992.
202. [202] Sanderson, L.M., Degenhardt, T., Koppen, A., Kalkhoven, E., Desvergne, B., Muller, M., Kersten, S., Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) but not PPARalpha serves as a plasma free fatty acid sensor in liver. Mol. Cell. Biol. 29 (2009), 6257–6267.
203. [203] Qin, X., Xie, X., Fan, Y., Tian, J., Guan, Y., Wang, X., Zhu, Y., Wang, N., Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology 48 (2008), 432–441.
204. −/− mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity. J. Lipid Res. 55 (2014), 1254–1266.
205. [205] Garbacz, W.G., Huang, J.T.J., Higgins, L.G., Wahli, W., Palmer, C.N.A., PPARα is required for PPARδ action in regulation of body weight and hepatic steatosis in mice. PPAR Res., 2015, 2015, 927057.
206. [206] Lee, C.H., Olson, P., Hevener, A., Mehl, I., Chong, L.W., Olefsky, J.M., Gonzalez, F.J., Ham, J., Kang, H., Peters, J.M., Evans, R.M., PPARdelta regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 3444–3449.
207. [207] Liu, S., Hatano, B., Zhao, M., Yen, C.C., Kang, K., Reilly, S.M., Gangl, M.R., Gorgun, C., Balschi, J.A., Ntambi, J.M., Lee, C.H., Role of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulation. J. Biol. Chem. 286 (2011), 1237–1247.
208. [208] Montagner, A., Polizzi, A., Fouché, E., Ducheix, S., Lippi, Y., Lasserre, F., Barquissau, V., Régnier, M., Lukowicz, C., Benhamed, F., Iroz, A., Bertrand-Michel, J., Al Saati, T., Cano, P., Mselli-Lakhal, L., Mithieux, G., Rajas, F., Lagarrigue, S., Pineau, T., Loiseau, N., Postic, C., Langin, D., Wahli, W., Guillou, H., Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut 65 (2016), 1202–1214.
209. [209] Shan, W., Nicol, C.J., Ito, S., Bility, M.T., Kennett, M.J., Ward, J.M., Gonzalez, F.J., Peters, J.M., Peroxisome proliferator-activated receptor-β/δ protects against chemically induced liver toxicity in mice. Hepatology 47 (2008), 225–235.
210. [210] Odegaard, J.I., Ricardo-Gonzalez, R.R., Red Eagle, A., Vats, D., Morel, C.R., Goforth, M.H., Subramanian, V., Mukundan, L., Ferrante, A.W., Chawla, A., Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance. Cell Metab. 7 (2008), 496–507.
211. [211] Friedman, S.L., Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275 (2000), 2247–2250.
212. [212] Hellemans, K., Michalik, L., Dittie, A., Knorr, A., Rombouts, K., de Jong, J., Heirman, C., Quartier, E., Schuit, F., Wahli, W., Geerts, A., Peroxisome proliferator-activated receptor-β signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 124 (2003), 184–201.
213. [213] Hellemans, K., Rombouts, K., Quartier, E., Dittie, A.S., Knorr, A., Michalik, L., Rogiers, V., Schuit, F., Wahli, W., Geerts, A., PPARbeta regulates vitamin a metabolism-related gene expression in hepatic stellate cells undergoing activation. J. Lipid Res. 44 (2003), 280–295.
214. [214] Iwaisako, K., Haimerl, M., Paik, Y.H., Taura, K., Kodama, Y., Sirlin, C., Yu, E., Yu, R.T., Downes, M., Evans, R.M., Brenner, D.A., Schnabl, B., Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E1369–E1376.
215. [215] Kostadinova, R., Montagner, A., Gouranton, E., Fleury, S., Guillou, H., Dombrowicz, D., Desreumaux, P., Wahli, W., GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. Cell Biophys., 2, 2012, 34.
216. [216] Cho, Y.M., Fujita, Y., Kieffer, T.J., Glucagon-like peptide-1: glucose homeostasis and beyond. Annu. Rev. Physiol. 76 (2014), 535–559.
217. [217] Daoudi, M., Hennuyer, N., Borland, M.G., Touche, V., Duhem, C., Gross, B., Caiazzo, R., Kerr-Conte, J., Pattou, F., Peters, J.M., Staels, B., Lestavel, S., PPARβ/δ activation induces enteroendocrine L Cell GLP-1 production. Gastroenterology 140 (2011), 1564–1574.
218. [218] Tang, T., Abbott, M.J., Ahmadian, M., Lopes, A.B., Wang, Y., Sul, H.S., Desnutrin/ATGL activates PPARδ to promote mitochondrial function for insulin secretion in islet β cells. Cell Metab. 18 (2013), 883–895.
219. [219] Winzell, M.S., Wulff, E.M., Olsen, G.S., Sauerberg, P., Gotfredsen, C.F., Ahrén, B., Improved insulin sensitivity and islet function after PPARδ activation in diabetic db/db mice. Eur. J. Pharmacol. 626 (2010), 297–305.
220. [220] Iglesias, J., Barg, S., Vallois, D., Lahiri, S., Roger, C., Yessoufou, A., Pradevand, S., McDonald, A., Bonal, C., Reimann, F., Gribble, F., Debril, M.-B., Metzger, D., Chambon, P., Herrera, P., Rutter, G.A., Prentki, M., Thorens, B., Wahli, W., PPARβ/δ affects pancreatic β cell mass and insulin secretion in mice. J. Clin. Investig. 122 (2012), 4105–4117.
221. [221] Varnat, F., Heggeler, B.B.T., Grisel, P., Boucard, N., Corthésy-Theulaz, I., Wahli, W., Desvergne, B., PPARβ/δ regulates paneth cell differentiation via controlling the Hedgehog signaling pathway. Gastroenterology 131 (2006), 538–553.
222. [222] Fearon, E.R., Vogelstein, B., A genetic model for colorectal tumorigenesis. Cell 61 (1990), 759–767.
223. [223] Groden, J., Thliveris, A., Samowitz, W., Carlson, M., Gelbert, L., Albertsen, H., Joslyn, G., Stevens, J., Spirio, L., Robertson, M., Sargeant, L., Krapcho, K., Wolff, E., Burt, R., Hughes, J.P., Warrington, J., McPherson, J., Wasmuth, J., Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66 (1991), 589–600.
224. [224] Nishisho, I., Nakamura, Y., Miyoshi, Y., Miki, Y., Ando, H., Horii, A., Koyama, K., Utsunomiya, J., Baba, S., Hedge, P., Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253 (1991), 665–669.
225. [225] Neufert, C., Becker, C., Neurath, M.F., An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat. Protoc. 2 (2007), 1998–2004.
226. [226] He, T.-C., Chan, T.A., Vogelstein, B., Kinzler, K.W., PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99 (1999), 335–345.
227. [227] Wang, D., Wang, H., Guo, Y., Ning, W., Katkuri, S., Wahli, W., Desvergne, B., Dey, S.K., DuBois, R.N., Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 19069–19074.
228. [228] Harman, F.S., Nicol, C.J., Marin, H.E., Ward, J.M., Gonzalez, F.J., Peters, J.M., Peroxisome proliferator–activated receptor-δ attenuates colon carcinogenesis. Nat. Med. 10 (2004), 481–483.
229. [229] Marin, H.E., Peraza, M.A., Billin, A.N., Willson, T.M., Ward, J.M., Kennett, M.J., Gonzalez, F.J., Peters, J.M., Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res. 66 (2006), 4394–4401.
230. [230] Beyaz, S., Mana, M.D., Roper, J., Kedrin, D., Saadatpour, A., Hong, S.-J., Bauer-Rowe, K.E., Xifaras, M.E., Akkad, A., Arias, E., Pinello, L., Katz, Y., Shinagare, S., Abu-Remaileh, M., Mihaylova, M.M., Lamming, D.W., Dogum, R., Guo, G., Bell, G.W., Selig, M., Nielsen, G.P., Gupta, N., Ferrone, C.R., Deshpande, V., Yuan, G.-C., Orkin, S.H., Sabatini, D.M., Yilmaz, Ö.H., High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. Nature 531 (2016), 53–58.
231. [231] Reed, K.R., Sansom, O.J., Hayes, A.J., Gescher, A.J., Winton, D.J., Peters, J.M., Clarke, A.R., PPARδ status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 23 (2004), 8992–8996.
232. [232] Hollingshead, H.E., Borland, M.G., Billin, A.N., Willson, T.M., Gonzalez, F.J., Peters, J.M., Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis 29 (2008), 169–176.
233. [233] Gupta, R.A., Wang, D., Katkuri, S., Wang, H., Dey, S.K., DuBois, R.N., Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat. Med. 10 (2004), 245–247.
234. [234] Luo, C., Puigserver, P., Stem cells: dietary fat promotes intestinal dysregulation. Nature 531 (2016), 42–43.
235. [235] Gupta, R.A., Tan, J., Krause, W.F., Geraci, M.W., Willson, T.M., Dey, S.K., DuBois, R.N., Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 13275–13280.
236. [236] Delage, B., Rullier, A., Capdepont, M., Rullier, E., Cassand, P., The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutr. J., 6, 2007, 20.
237. [237] Yang, L., Zhou, Z.G., Luo, H.Z., Zhou, B., Xia, Q.J., Tian, C., Quantitative analysis of PPARδ mRNA by real-time RT-PCR in 86 rectal cancer tissues. Eur. J. Surg. Oncol. 32 (2006), 181–185.
238. [238] Foreman, J.E., Chang, W.-C.L., Palkar, P.S., Zhu, B., Borland, M.G., Williams, J.L., Kramer, L.R., Clapper, M.L., Gonzalez, F.J., Peters, J.M., Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer. Mol. Carcinog. 50 (2011), 884–900.
239. [239] Feilchenfeldt, J., Bründler, M.-A., Soravia, C., Tötsch, M., Meier, C.A., Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARγ-coactivator 1 (PGC-1). Cancer Lett. 203 (2004), 25–33.
240. [240] Neels, J.G., Grimaldi, P.A., Physiological functions of peroxisome proliferator-activated receptor β. Physiol. Rev. 94 (2014), 795–858.
241. [241] Girroir, E.E., Hollingshead, H.E., He, P., Zhu, B., Perdew, G.H., Peters, J.M., Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice. Biochem. Biophys. Res. Commun. 371 (2008), 456–461.
242. [242] Peters, J.M., Hollingshead, H.E., Gonzalez, F.J., Role of peroxisome-proliferator-activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clin. Sci. 115 (2008), 107–127.
243. [243] McCart, A.E., Vickaryous, N.K., Silver, A., Apc mice: models, modifiers and mutants. Pathol. Res. Pract. 204 (2008), 479–490.
244. [244] Dove, W.F., Cormier, R.T., Gould, K.A., Halberg, R.B., Merritt, A.J., Newton, M.A., Shoemaker, A.R., The intestinal epithelium and its neoplasms: genetic, cellular and tissue interactions. Philos. Trans. R. Soc., B 353 (1998), 915–923.
245. + mice. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 10826–10831.
246. [246] Karantanos, T., Theodoropoulos, G., Pektasides, D., Gazouli, M., Clock genes: their role in colorectal cancer. World J. Gastroenterol. 20 (2014), 1986–1992.
247. [247] Karantanos, T., Theodoropoulos, G., Gazouli, M., Vaiopoulou, A., Karantanou, C., Stravopodis, D.J., Bramis, K., Lymperi, M., Pektasidis, D., Association of the clock genes polymorphisms with colorectal cancer susceptibility. J. Surg. Oncol. 108 (2013), 563–567.
248. [248] Johnson, C.H., Dejea, C.M., Edler, D., Hoang, L.T., Santidrian, A.F., Felding, B.H., Ivanisevic, J., Cho, K., Wick, E.C., Hechenbleikner, E.M., Uritboonthai, W., Goetz, L., Casero, R.A., Pardoll, D.M., White, J.R., Patti, G.J., Sears, C.L., Siuzdak, G., Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab. 21 (2015), 891–897.
249. [249] Montagner, A., Wahli, W., Tan, N.S., Nuclear receptor peroxisome proliferator activated receptor (PPAR) beta/delta in skin wound healing and cancer. Eur. J. Dermatol. 25 (2015), 4–11.
250. [250] Cataisson, C., Joseloff, E., Murillas, R., Wang, A., Atwell, C., Torgerson, S., Gerdes, M., Subleski, J., Gao, J.L., Murphy, P.M., Wiltrout, R.H., Vinson, C., Yuspa, S.H., Activation of cutaneous protein kinase C alpha induces keratinocyte apoptosis and intraepidermal inflammation by independent signaling pathways. J. Immunol. 171 (2003), 2703–2713.
251. [251] Wang, H.Q., Smart, R.C., Overexpression of protein kinase C-alpha in the epidermis of transgenic mice results in striking alterations in phorbol ester-induced inflammation and COX-2, MIP-2 and TNF-alpha expression but not tumor promotion. J. Cell Sci. 112 (1999), 3497–3506.
252. [252] Nakatsu, G., Li, X., Zhou, H., Sheng, J., Wong, S.H., Wu, W.K.K., Ng, S.C., Tsoi, H., Dong, Y., Zhang, N., He, Y., Kang, Q., Cao, L., Wang, K., Zhang, J., Liang, Q., Yu, J., Sung, J.J.Y., Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat. Commun., 6, 2015, 8727.
253. [253] Ehrhart, J.-C., Gosselet, F.P., Culerrier, R.L.M., Sarasin, A., UVB-induced mutations in human key gatekeeper genes governing signalling pathways and consequences for skin tumourigenesis. Photochem. Photobiol. Sci. 2 (2003), 825–834.
254. [254] Matsumura, Y., Ananthaswamy, H.N., Toxic effects of ultraviolet radiation on the skin. Toxicol. Appl. Pharmacol. 195 (2004), 298–308.
255. [255] Montagner, A., Delgado, M.B., Tallichet-Blanc, C., Chan, J.S.K., Sng, M.K., Mottaz, H., Degueurce, G., Lippi, Y., Moret, C., Baruchet, M., Antsiferova, M., Werner, S., Hohl, D., Al Saati, T., Farmer, P.J., Tan, N.S., Michalik, L., Wahli, W., Src is activated by the nuclear receptor peroxisome proliferator-activated receptor β/δ in ultraviolet radiation-induced skin cancer. EMBO Mol. Med. 6 (2014), 80–98.
256. [256] Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
257. [257] Bondar, T., Medzhitov, R., The origins of tumor-promoting inflammation. Cancer Cell 24 (2013), 143–144.
258. [258] Degueurce, G., D'Errico, I., Pich, C., Ibberson, M., Schütz, F., Montagner, A., Sgandurra, M., Mury, L., Jafari, P., Boda, A., Meunier, J., Rezzonico, R., Brembilla, N.C., Hohl, D., Kolios, A., Hofbauer, G., Xenarios, I., Michalik, L., Identification of a novel PPARβ/δ/miR-21-3p axis in UV-induced skin inflammation. EMBO Mol. Med. 8 (2016), 919–936.
259. [259] Kim, D.J., Akiyama, T.E., Harman, F.S., Burns, A.M., Shan, W., Ward, J.M., Kennett, M.J., Gonzalez, F.J., Peters, J.M., Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J. Biol. Chem. 279 (2004), 23719–23727.
260. [260] Bility, M.T., Devlin-Durante, M.K., Blazanin, N., Glick, A.B., Ward, J.M., Kang, B.H., Kennett, M.J., Gonzalez, F.J., Peters, J.M., Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis. Carcinogenesis 29 (2008), 2406–2414.
261. [261] Boukamp, P., Non-melanoma skin cancer: what drives tumor development and progression?. Carcinogenesis 26 (2005), 1657–1667.
262. [262] Abel, E.L., Angel, J.M., Kiguchi, K., DiGiovanni, J., Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat. Protoc. 4 (2009), 1350–1362.
263. [263] Lieu, F.M., Yamanishi, K., Konishi, K., Kishimoto, S., Yasuno, H., Low incidence of Ha-ras oncogene mutations in human epidermal tumors. Cancer Lett. 59 (1991), 231–235.
264. [264] Pierceall, W.E., Goldberg, L.H., Tainsky, M.A., Mukhopadhyay, T., Ananthaswamy, H.N., Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol. Carcinog. 4 (1991), 196–202.
265. [265] Campbell, C., Quinn, A.G., Rees, J.L., Codon 12 Harvey-ras mutations are rare events in non-melanoma human skin cancer. Br. J. Dermatol. 128 (1993), 111–114.
266. [266] Kim, H.J., Ham, S.A., Kim, S.U., Hwang, J.Y., Kim, J.H., Chang, K.C., Yabe-Nishimura, C., Kim, J.H., Seo, H.G., Transforming growth factor-beta1 is a molecular target for the peroxisome proliferator-activated receptor delta. Circ. Res. 102 (2008), 193–200.
267. [267] Glick, A.B., TGF? Back to the future: revisiting its role as a transforming growth factor. Cancer Biol. Ther. 3 (2004), 276–283.
268. [268] Mordasky Markell, L., Perez-Lorenzo, R., Masiuk, K.E., Kennett, M.J., Glick, A.B., Use of a TGFbeta type I receptor inhibitor in mouse skin carcinogenesis reveals a dual role for TGFbeta signaling in tumor promotion and progression. Carcinogenesis 31 (2010), 2127–2135.
269. [269] Cui, W., Fowlis, D.J., Bryson, S., Duffie, E., Ireland, H., Balmain, A., Akhurst, R.J., TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86 (1996), 531–542.
270. [270] Glick, A.B., The role of TGFβ signaling in squamous cell cancer: lessons from mouse models. J. Skin Cancer, 2012, 2012, 249063.
271. [271] Ravindran, A., Mohammed, J., Gunderson, A.J., Cui, X., Glick, A.B., Tumor-promoting role of TGFβ1 signaling in ultraviolet B-induced skin carcinogenesis is associated with cutaneous inflammation and lymph node migration of dermal dendritic cells. Carcinogenesis 35 (2014), 959–966.
272. [272] Ikushima, H., Miyazono, K., Cellular context-dependent “colors” of transforming growth factor-β signaling. Cancer Sci. 101 (2010), 306–312.
273. [273] Papageorgis, P., TGFβ signaling in tumor initiation, epithelial-to-mesenchymal transition, and metastasis. J. Oncol., 2015, 2015, 587193.
274. [274] Tan, N.S., Michalik, L., Noy, N., Yasmin, R., Pacot, C., Heim, M., Fluhmann, B., Desvergne, B., Wahli, W., Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev. 15 (2001), 3263–3277.
275. [275] Burdick, A.D., Bility, M.T., Girroir, E.E., Billin, A.N., Willson, T.M., Gonzalez, F.J., Peters, J.M., Ligand activation of peroxisome proliferator-activated receptor-β/δ(PPARβ/δ) inhibits cell growth of human N/TERT-1 keratinocytes. Cell. Signal. 19 (2007), 1163–1171.
276. [276] Peters, J.M., Gonzalez, F.J., Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in cell proliferation and cancer. Biochem. Biophys. Res. Commun. 1796 (2009), 230–241.
277. [277] Rognoni, E., Widmaier, M., Jakobson, M., Ruppert, R., Ussar, S., Katsougkri, D., Böttcher, R.T., Lai-Cheong, J.E., Rifkin, D.B., McGrath, J.A., Fässler, R., Kindlin-1 controls Wnt and TGF-β availability to regulate cutaneous stem cell proliferation. Nat. Med. 20 (2014), 350–359.
278. [278] Seo, H.R., Kwan, Y.-W., Cho, C.-K., Bae, S., Lee, S.-J., Soh, J.-W., Chung, H.-Y., Lee, Y.-S., PKCα induces differentiation through ERK1/2 phosphorylation in mouse keratinocytes. Exp. Mol. Med. 36 (2004), 292–299.
279. [279] Kocalis, H.E., Turney, M.K., Printz, R.L., Laryea, G.N., Muglia, L.J., Davies, S.S., Stanwood, G.D., McGuinness, O.P., Niswender, K.D., Neuron-specific deletion of peroxisome proliferator-activated receptor delta (PPARδ) in mice leads to increased susceptibility to diet-induced obesity. PLoS One, 7, 2012, e42981.
280. [280] Iwashita, A., Muramatsu, Y., Yamazaki, T., Muramoto, M., Kita, Y., Yamazaki, S., Mihara, K., Moriguchi, A., Matsuoka, N., Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo. J. Pharmacol. Exp. Ther. 320 (2007), 1087–1096.
281. [281] Schnegg, C.I., Robbins, M.E., Neuroprotective mechanisms of PPARδ: modulation of oxidative stress and inflammatory processes. PPAR Res., 2011, 2011, 373560.
282. [282] Woods, J.W., Tanen, M., Figueroa, D.J., Biswas, C., Zycband, E., Moller, D.E., Austin, C.P., Berger, J.P., Localization of PPARδ in murine central nervous system: expression in oligodendrocytes and neurons. Brain Res. 975 (2003), 10–21.
283. [283] Paterniti, I., Esposito, E., Mazzon, E., Galuppo, M., Di Paola, R., Bramanti, P., Kapoor, A., Thiemermann, C., Cuzzocrea, S., Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury. J. Pharmacol. Exp. Ther. 333 (2010), 465–477.
284. [284] Hall, M.G., Quignodon, L., Desvergne, B., Peroxisome proliferator-activated receptorβ/δin the brain: facts and hypothesis. PPAR Res., 2008, 2008, 780452.
285. [285] Aleshin, S., Strokin, M., Sergeeva, M., Reiser, G., Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: review and novel hypotheses. Neurochem. Int. 63 (2013), 322–330.
286. [286] Dunn, S.E., Bhat, R., Straus, D.S., Sobel, R.A., Axtell, R., Johnson, A., Nguyen, K., Mukundan, L., Moshkova, M., Dugas, J.C., Chawla, A., Steinman, L., Peroxisome proliferator-activated receptor δ limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J. Exp. Med. 207 (2010), 1599–1608.
287. [287] Arsenijevic, D., de Bilbao, F., Plamondon, J., Paradis, E., Vallet, P., Richard, D., Langhans, W., Giannakopoulos, P., Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor β-deficient mice. J. Cereb. Blood Flow Metab. 26 (2006), 433–445.
288. [288] Zhang, N., Yin, Y., Xu, S.J., Wu, Y.P., Chen, W.S., Inflammation & apoptosis in spinal cord injury. Indian J. Med. Res. 135 (2012), 287–296.
289. [289] Paterniti, I., Impellizzeri, D., Crupi, R., Morabito, R., Campolo, M., Esposito, E., Cuzzocrea, S., Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. J. Neuroinflammation, 10, 2013, 20.
290. [290] Polak, P.E., Kalinin, S., Dello Russo, C., Gavrilyuk, V., Sharp, A., Peters, J.M., Richardson, J., Willson, T.M., Weinberg, G., Feinstein, D.L., Protective effects of a peroxisome proliferator-activated receptor-β/δ agonist in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 168 (2005), 65–75.
291. [291] Fletcher, J.M., Lalor, S.J., Sweeney, C.M., Tubridy, N., Mills, K.H.G., T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 162 (2010), 1–11.
292. [292] Kanakasabai, S., Chearwae, W., Walline, C.C., Iams, W., Adams, S.M., Bright, J.J., Peroxisome proliferator-activated receptor δ agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology 130 (2010), 572–588.
293. [293] Mufson, E.J., Ikonomovic, M.D., Counts, S.E., Perez, S.E., Malek-Ahmadi, M., Scheff, S.W., Ginsberg, S.D., Molecular and cellular pathophysiology of preclinical Alzheimer's disease. Behav. Brain Res. 311 (2016), 54–69.
294. [294] Kandalepas, P., Vassar, R., The normal and pathologic roles of the Alzheimer's β-secretase, BACE1. Curr. Alzheimer Res. 11 (2014), 441–449.
295. [295] Ohno, M., Alzheimer's therapy targeting the β-secretase enzyme BACE1: benefits and potential limitations from the perspective of animal model studies. Brain Res. Bull., 2016.
296. [296] Schmidt, A.M., Sahagan, B., Nelson, R.B., Selmer, J., Rothlein, R., Bell, J.M., The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr. Opin. Investig. Drugs 10 (2009), 672–680.
297. [297] Khan, S.S., Bloom, G.S., Tau: the center of a signaling nexus in Alzheimer's disease. Front. Neurosci., 10, 2016, 31.
298. [298] Cai, Z., Liu, N., Wang, C., Qin, B., Zhou, Y., Xiao, M., Chang, L., Yan, L.-J., Zhao, B., Role of RAGE in Alzheimer's disease. Cell. Mol. Neurobiol. 36 (2016), 483–495.
299. [299] Kalinin, S., Richardson, J., Feinstein, D., A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr. Alzheimer Res. 6 (2009), 431–437.
300. [300] Barroso, E., del Valle, J., Porquet, D., Vieira Santos, A.M., Salvadó, L., Rodríguez-Rodríguez, R., Gutiérrez, P., Anglada-Huguet, M., Alberch, J., Camins, A., Palomer, X., Pallàs, M., Michalik, L., Wahli, W., Vázquez-Carrera, M., Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARβ/δ-null mice. Biochim. Biophys. Acta 1832 (2013), 1241–1248.
301. [301] Malm, T., Mariani, M., Donovan, L.J., Neilson, L., Landreth, G.E., Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation. J. Neuroinflammation, 12, 2015, 7.
302. [302] Lester-Coll, N., Rivera, E.J., Soscia, S.J., Doiron, K., Wands, J.R., de la Monte, S.M., Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J. Alzheimers Dis. 9 (2006), 13–33.
303. [303] de la Monte, S.M., Wands, J.R., Alzheimer's disease is type 3 diabetes—evidence reviewed. J. Diabet. Sci. Technol. 2 (2008), 1101–1113.
304. [304] Falcone, R., Marilena Florio, T., Giacomo, E.D., Benedetti, E., Cristiano, L., Antonosante, A., Fidoamore, A., Massimi, M., Alecci, M., Ippoliti, R., Giordano, A., Cimini, A., PPARβ/δ and γ in a rat model of Parkinson's disease: possible involvement in PD symptoms. J. Cell. Biochem. 116 (2015), 844–855.
305. [305] de la Monte, S.M., Tong, M., Lester-Coll, N., Plater, M. Jr., Wands, J.R., Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J. Alzheimers Dis. 10 (2006), 89–109.
306. [306] Tong, M., Dominguez, C., Targeting Alzheimer's disease neuro-metabolic dysfunction with a small molecule nuclear receptor agonist (T3D-959) reverses dise ase pathologies. J. Alzheimers Dis. Parkinsonism, 6, 2016, 238.
307. [307] Tong, M., Deochand, C., Didsbury, J., de la Monte, S.M., T3D-959: a multi-faceted disease remedial drug candidate for the treatment of Alzheimer's disease. J. Alzheimers Dis. 51 (2016), 123–138.
308. [308] de la Monte, S.M., Wands, J.R., Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J. Alzheimers Dis. 9 (2006), 167–181.
309. [309] Weingarten, H.L., 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): one designer drug and serendipity. J. Foren. Sci. 33 (1988), 588–595.
310. [310] Davie, C.A., A review of Parkinson's disease. Br. Med. Bull. 86 (2008), 109–127.
311. [311] Kopin, I.J., Markey, S.P., MPTP toxicity: implications for research in Parkinson's disease. Annu. Rev. Neurosci. 11 (1988), 81–96.
312. [312] Jackson-Lewis, V., Przedborski, S., Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2 (2007), 141–151.
313. [313] Sian, J., Youdim, M., Riederer, P., Gerlach, M., MPTP-induced parkinsonian syndrome. Siegel, G.J., Agranoff, B.W., Albers, R.W., Fisher, S.K., Uhler, M.D., (eds.) Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 1998, Lippincott Williams & Wilkins, Philadelphia.
314. [314] Martin, H.L., Mounsey, R.B., Sathe, K., Mustafa, S., Nelson, M.C., Evans, R.M., Teismann, P., A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neuroscience 240 (2013), 191–203.
315. [315] Deumens, R., Blokland, A., Prickaerts, J., Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175 (2002), 303–317.
316. [316] Dickey, A.S., Pineda, V.V., Tsunemi, T., Liu, P.P., Miranda, H.C., Gilmore-Hall, S.K., Lomas, N., Sampat, K.R., Buttgereit, A., Torres, M.-J.M., Flores, A.L., Arreola, M., Arbez, N., Akimov, S.S., Gaasterland, T., Lazarowski, E.R., Ross, C.A., Yeo, G.W., Sopher, B.L., Magnuson, G.K., Pinkerton, A.B., Masliah, E., La Spada, A.R., PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically. Nat. Med. 22 (2016), 37–45.
317. [317] Cheng, Y., Single-particle Cryo-EM at crystallographic resolution. Cell 161 (2015), 450–457.
318. [318] Henderson, R., Overview and future of single particle electron cryomicroscopy. Arch. Biochem. Biophys. 581 (2015), 19–24.
319. [319] Nogales, E., Scheres, S.H.W., Cryo-EM: a unique tool for the visualization of macromolecular complexity. Mol. Cell 58 (2015), 677–689.
320. [320] Lyons, J.A., Shahsavar, A., Paulsen, P.A., Pedersen, B.P., Nissen, P., Expression strategies for structural studies of eukaryotic membrane proteins. Curr. Opin. Struct. Biol. 38 (2016), 137–144.
321. [321] Kahremany, S., Livne, A., Gruzman, A., Senderowitz, H., Sasson, S., Activation of PPARδ: from computer modelling to biological effects. Br. J. Pharmacol. 172 (2015), 754–770.